🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Pilot Study to Evaluate the Feasibility, Adherence and Acceptance of the MiDiálisis Platform for Patients on PD

RecruitingNAAges 18 Years - anyAllAida Frías González
NCT07326085 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The main goal of this study is to assess whether a mobile phone app called MiDiálisis is practical, easy to use, and well-accepted. The app was developed by the Technical University of Madrid (UPM) and is designed to bring together the clinical data of people with chronic kidney disease who are on peritoneal dialysis. This way, both patients and doctors can access the information at any time.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients over 18 years of age. * Patients with chronic kidney disease who have been on PD for at least 3 months in the same hospital. * Patients with a stable clinical condition during the 3 months prior to entering the study, defined as no unscheduled hospitalizations or major cardiovascular events (myocardial infarction or stroke) during that period. * Availability of a smartphone or tablet and internet access for the patient/caregiver. * Patients who understand the nature of the study and sign the informed consent form. Exclusion Criteria: * Patients with limitations for multifrequency body composition measurement (pacemaker or implantable cardioverter defibrillator wearers, and pregnant women). * Patients who do not routinely use a smartphone or are unfamiliar with the use of mobile applications. * Patients who are scheduled for a living kidney transplant in the next 6 months. * Patients with a life expectancy of less than 6 months. * Patients in a peritoneal ultrafiltration program due to cardiorenal syndrome.
💊

What it tests

  • Smart band
  • Smart scale
  • MiDialisis App
  • Patients will install the app during the phase 2.
  • Patients will connect the digital scale.
📍

Where

1 site
Hospital 12 de Octubre
Madrid, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy